Financials data is unavailable for this security.
View more
Year on year Recce Pharmaceuticals Ltd had net income fall 35.06% from a loss of 13.08m to a larger loss of 17.66m despite a 18.17% increase in revenues from 4.43m to 5.24m. An increase in the selling, general and administrative costs as a percentage of sales from 357.85% to 388.16% was a component in the falling net income despite rising revenues.
| Gross margin | -- |
|---|---|
| Net profit margin | -337.29% |
| Operating margin | -321.12% |
| Return on assets | -395.76% |
|---|---|
| Return on equity | -- |
| Return on investment | -- |
More ▼
Cash flow in AUDView more
In 2024, Recce Pharmaceuticals Ltd increased its cash reserves by 182.74%, or 2.85m. Cash Flow from Financing totalled 16.00m or 305.63% of revenues. In addition the company used 13.01m for operations while cash used for investing totalled 141.90k.
| Cash flow per share | -0.0977 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | -0.0467 |
|---|---|
| Tangible book value per share | -0.0467 |
More ▼
Balance sheet in AUDView more
| Current ratio | 0.3409 |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | -- |
|---|---|
| Total debt/total capital | -- |
More ▼
